What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Baricitinib demonstrated moderate clinical effectiveness in improving hair regrowth after 36 weeks compared to placebo, with a treatment response rate of approximately 34% achieving a SALT score of 20 or less. However, the need for ongoing treatment to maintain hair regrowth and the lack of significant improvements in health-related quality of life measures limit the perceived clinical benefit.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for baricitinib were found to be uncertain and significantly higher than the thresholds typically considered acceptable by NICE, ranging from £36,407 to £252,710 per QALY gained. This indicates that baricitinib does not represent a cost-effective use of Healthcare resources.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence indicates that baricitinib did not show meaningful improvements in most health-related quality of life assessments compared to placebo. While some specific domains showed statistically significant improvements, the overall impact on HRQoL was not clinically meaningful, suggesting no demonstrated benefit.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Baricitinib was reported to have a favorable short-term safety profile compared to placebo, with mild adverse events that did not significantly detract from health-related quality of life. Long-term safety concerns exist, particularly regarding cardiovascular events and cancer, but these are primarily based on data from other conditions.
Was the drug compared against what payers expect? — Comparator Selection
The trials primarily compared baricitinib against placebo, which is acceptable for assessing efficacy but does not provide direct comparisons with existing treatments for severe alopecia areata. The committee noted that comparisons with active treatments used in the Healthcare would have been more informative.
Is the population defined the way payers need it? — Patient Population and Subgroups
The BRAVE trials included a population that is broadly generalizable to those likely to receive baricitinib in the Healthcare, although there were concerns regarding the representation of individuals with varying levels of psychological impact from the condition. The inclusion of diverse demographics enhances the relevance of the findings.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Baricitinib is positioned within the treatment pathway for severe alopecia areata similarly to other systemic treatments, suggesting it can be integrated into existing care practices with manageable adjustments. The committee noted that it would be the first licensed option for this condition.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model indicated a high resource burden associated with baricitinib, raising concerns about its affordability within the Healthcare. The uncertainty surrounding the cost-effectiveness and the high ICER values suggest that the resource implications are significant.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by two Phase 3 randomized controlled trials (BRAVE-AA1 and BRAVE-AA2), which were deemed adequately powered and of high quality. However, there are some methodological concerns regarding the generalizability of the trial populations to the broader Healthcare context.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term effectiveness of baricitinib, particularly in treatment-naive populations and its impact on health-related quality of life. The committee noted that these uncertainties could restrict its use and that further research is needed.
